Product News: Trimix Advances to Next Stage in Clinical Trials

The tripartite mRNA technology has completed its phase 1b study for direct, intranodal injections in adjuvant melanoma patients

04 Mar 2019


eTheRNA immunotherapies, a clinical-stage company developing cancer immunotherapies based on its proprietary mRNA TriMix platform, has announced the completion of the high-dose cohort of its Phase 1b study (E011-MEL) evaluating ECI-006 (TriMix with tumor specific antigens) in an adjuvant setting in melanoma patients after surgical removal of lesions. The E011-MEL study confirms the feasibility of developing mRNA immunotherapy for direct injection intranodally, in addition to a previously used dendritic cell infusion-based approach.

The E011-MEL Phase 1b study was designed to evaluate intranodal (injection into the inguinal lymph nodes) administration of ECI-006 in adjuvant melanoma patients. ECI-006 is a TriMix-based immunotherapy boosted with mRNA encoding melanoma tumor-specific antigens. The study comprises a low-dose and a high-dose cohort, each enrolling 10 patients. Investigative centers were in Belgium and Spain. The objective of the study is to assess safety and tolerability of mRNA administered intranodally and to seek evidence of immune-stimulation.

Completion of enrolment of the low-dose cohort was reported previously in March 2018, along with initial safety data. No adverse safety signals were observed in the low-dose cohort, which has already completed its dosing phase.

Today, the company reports completion of patient recruitment for the high-dose cohort.  No adverse safety signals were observed in the high-dose cohort either. Results from the immunomonitoring of the immunological responses elicited by ECI 006 will be presented at a later date.

Dr. Bertil Lindmark, Chief Medical Officer, eTheRNA immunotherapies commented: “With this study we have shown that intranodal injection of an mRNA based immunostimulatory vaccine is clinically feasible and well tolerated. This is an important result as it advances our strategy to develop mRNA-based immunotherapies to treat patients with cancer. The ECI-006 can effectively induce immune priming so that we may see amplified efficacy when combined with a checkpoint inhibitor”.